Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ONCO |
---|---|---|
09:32 ET | 503 | 1.06 |
09:33 ET | 199 | 1.06 |
09:35 ET | 2000 | 1.06 |
09:39 ET | 1344 | 1.06 |
09:51 ET | 636 | 1.0783 |
10:00 ET | 1000 | 1.055 |
10:02 ET | 2000 | 1.0401 |
10:08 ET | 1000 | 1.03 |
10:13 ET | 255 | 1.0362 |
10:18 ET | 100 | 1.03 |
10:20 ET | 200 | 1.03 |
10:22 ET | 1827 | 1.05 |
10:24 ET | 787 | 1.0508 |
10:31 ET | 100 | 1.07 |
10:36 ET | 300 | 1.06 |
10:40 ET | 100 | 1.05 |
10:42 ET | 519 | 1.05 |
10:44 ET | 100 | 1.03 |
10:45 ET | 800 | 1.05 |
10:49 ET | 600 | 1.04 |
10:51 ET | 294 | 1.03 |
10:54 ET | 2194 | 1.03 |
10:56 ET | 1200 | 1.045 |
10:58 ET | 200 | 1.04 |
11:07 ET | 2300 | 1.03 |
11:12 ET | 314 | 1.02 |
11:14 ET | 1300 | 1.0317 |
11:16 ET | 340 | 1.02 |
11:18 ET | 200 | 1.03 |
11:20 ET | 100 | 1.03 |
11:21 ET | 200 | 1.04 |
11:23 ET | 2100 | 1.06 |
11:30 ET | 100 | 1.04 |
11:32 ET | 300 | 1.04 |
11:36 ET | 100 | 1.03 |
11:41 ET | 300 | 1.03 |
11:43 ET | 300 | 1.04 |
11:48 ET | 100 | 1.03 |
11:50 ET | 100 | 1.03 |
11:52 ET | 100 | 1.03 |
11:54 ET | 100 | 1.03 |
11:56 ET | 100 | 1.03 |
12:03 ET | 200 | 1.03 |
12:06 ET | 200 | 1.03 |
12:08 ET | 100 | 1.03 |
12:10 ET | 300 | 1.03 |
12:14 ET | 100 | 1.03 |
12:15 ET | 200 | 1.03 |
12:17 ET | 100 | 1.03 |
12:21 ET | 300 | 1.0299 |
12:24 ET | 400 | 1.02 |
12:28 ET | 400 | 1.02 |
12:30 ET | 4760 | 1.03 |
12:42 ET | 1940 | 1.02 |
12:46 ET | 728 | 1.02 |
12:48 ET | 6828 | 0.9942 |
12:50 ET | 6550 | 0.9756 |
12:51 ET | 200 | 0.97 |
12:53 ET | 200 | 0.972 |
12:55 ET | 400 | 0.9588 |
12:57 ET | 700 | 0.9601 |
01:00 ET | 51900 | 0.86 |
01:02 ET | 900 | 0.86 |
01:04 ET | 900 | 0.86 |
01:06 ET | 800 | 0.8982 |
01:08 ET | 500 | 0.864201 |
01:09 ET | 700 | 0.84 |
01:11 ET | 2700 | 0.85275 |
01:13 ET | 1798 | 0.8654 |
01:15 ET | 1302 | 0.8651 |
01:18 ET | 2598 | 0.89 |
01:20 ET | 4553 | 0.895 |
01:22 ET | 1263 | 0.8651 |
01:27 ET | 10319 | 0.9098 |
01:29 ET | 5048 | 0.89 |
01:31 ET | 100 | 0.9 |
01:36 ET | 200 | 0.9048 |
01:38 ET | 300 | 0.8963 |
01:42 ET | 200 | 0.8963 |
01:44 ET | 200 | 0.89 |
01:45 ET | 200 | 0.8963 |
01:47 ET | 300 | 0.8963 |
01:51 ET | 1058 | 0.89 |
01:58 ET | 2600 | 0.875 |
02:00 ET | 420 | 0.89 |
02:02 ET | 450 | 0.8837 |
02:03 ET | 500 | 0.8986 |
02:05 ET | 1000 | 0.88269 |
02:09 ET | 100 | 0.8827 |
02:12 ET | 1475 | 0.8864 |
02:16 ET | 360 | 0.875 |
02:18 ET | 100 | 0.892028 |
02:21 ET | 2000 | 0.8929 |
02:25 ET | 100 | 0.9098 |
02:27 ET | 200 | 0.9 |
02:30 ET | 200 | 0.88614 |
02:38 ET | 300 | 0.8864 |
02:41 ET | 2900 | 0.8901 |
02:43 ET | 200 | 0.8901 |
02:45 ET | 212 | 0.8901 |
02:48 ET | 2573 | 0.8901 |
02:52 ET | 2963 | 0.89 |
02:54 ET | 244 | 0.89 |
02:56 ET | 200 | 0.89 |
02:57 ET | 100 | 0.89 |
03:01 ET | 425 | 0.892899 |
03:03 ET | 200 | 0.89 |
03:10 ET | 1486 | 0.89 |
03:12 ET | 200 | 0.8902 |
03:14 ET | 100 | 0.8901 |
03:15 ET | 999 | 0.8902 |
03:17 ET | 300 | 0.8888 |
03:19 ET | 500 | 0.8924 |
03:21 ET | 100 | 0.8888 |
03:24 ET | 228 | 0.8941 |
03:28 ET | 3426 | 0.893444 |
03:30 ET | 2084 | 0.9 |
03:32 ET | 2359 | 0.886 |
03:33 ET | 2273 | 0.8876 |
03:35 ET | 4400 | 0.8876 |
03:37 ET | 400 | 0.9 |
03:39 ET | 500 | 0.8876 |
03:42 ET | 400 | 0.8876 |
03:44 ET | 300 | 0.8881 |
03:46 ET | 2714 | 0.8989 |
03:48 ET | 400 | 0.8928 |
03:50 ET | 900 | 0.89 |
03:51 ET | 1100 | 0.8824 |
03:53 ET | 600 | 0.875 |
03:55 ET | 700 | 0.875 |
03:57 ET | 3188 | 0.8767 |
04:00 ET | 33016 | 0.8099 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Onconetix Inc | 9.0M | 0.0x | --- |
CeCors Inc | 9.0M | --- | --- |
StimCell Enegetics Inc | 8.9M | -27.4x | --- |
Evaxion Biotech A/S | 8.3M | -0.1x | --- |
Mustang Bio Inc | 9.8M | -0.1x | --- |
Bioxytran Inc | 8.2M | -4.9x | --- |
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.0M |
---|---|
Revenue (TTM) | $1.5M |
Shares Outstanding | 8.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-104.90 |
Book Value | $105.06 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,533.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.